JP7651557B2 - Iii型受容体チロシンキナーゼ阻害剤としてのヘテロ環式ピラゾール誘導体 - Google Patents

Iii型受容体チロシンキナーゼ阻害剤としてのヘテロ環式ピラゾール誘導体 Download PDF

Info

Publication number
JP7651557B2
JP7651557B2 JP2022511322A JP2022511322A JP7651557B2 JP 7651557 B2 JP7651557 B2 JP 7651557B2 JP 2022511322 A JP2022511322 A JP 2022511322A JP 2022511322 A JP2022511322 A JP 2022511322A JP 7651557 B2 JP7651557 B2 JP 7651557B2
Authority
JP
Japan
Prior art keywords
methyl
cyclopenta
dihydrothieno
indazol
pyrazol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022511322A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022545019A5 (cg-RX-API-DMAC7.html
JP2022545019A (ja
Inventor
シャオ-ツェン ペン,
チュ-ビン リャオ,
フン-ジュン ファン,
ユアン-ティン チョウ,
イ-メイ チャン,
ユ-チ パン,
Original Assignee
ディヴェロップメント センター フォー バイオテクノロジー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ディヴェロップメント センター フォー バイオテクノロジー filed Critical ディヴェロップメント センター フォー バイオテクノロジー
Publication of JP2022545019A publication Critical patent/JP2022545019A/ja
Publication of JP2022545019A5 publication Critical patent/JP2022545019A5/ja
Application granted granted Critical
Publication of JP7651557B2 publication Critical patent/JP7651557B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
JP2022511322A 2019-08-23 2020-08-22 Iii型受容体チロシンキナーゼ阻害剤としてのヘテロ環式ピラゾール誘導体 Active JP7651557B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962891097P 2019-08-23 2019-08-23
US62/891,097 2019-08-23
PCT/US2020/047552 WO2021041276A1 (en) 2019-08-23 2020-08-22 Heterocyclic pyrazole derivatives as type iii receptor tyrosine kinase inhibitors

Publications (3)

Publication Number Publication Date
JP2022545019A JP2022545019A (ja) 2022-10-24
JP2022545019A5 JP2022545019A5 (cg-RX-API-DMAC7.html) 2023-08-18
JP7651557B2 true JP7651557B2 (ja) 2025-03-26

Family

ID=74685735

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022511322A Active JP7651557B2 (ja) 2019-08-23 2020-08-22 Iii型受容体チロシンキナーゼ阻害剤としてのヘテロ環式ピラゾール誘導体

Country Status (11)

Country Link
US (1) US12448394B2 (cg-RX-API-DMAC7.html)
EP (1) EP4017853A4 (cg-RX-API-DMAC7.html)
JP (1) JP7651557B2 (cg-RX-API-DMAC7.html)
KR (1) KR20220051365A (cg-RX-API-DMAC7.html)
CN (1) CN114502553B (cg-RX-API-DMAC7.html)
AU (1) AU2020337883B2 (cg-RX-API-DMAC7.html)
BR (1) BR112022003383A2 (cg-RX-API-DMAC7.html)
CA (1) CA3151821A1 (cg-RX-API-DMAC7.html)
MX (1) MX2022002062A (cg-RX-API-DMAC7.html)
TW (1) TWI759829B (cg-RX-API-DMAC7.html)
WO (1) WO2021041276A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113278010A (zh) * 2021-06-01 2021-08-20 中国科学院上海有机化学研究所 一类蛋白激酶降解剂及其用途

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006502097A (ja) 2002-05-15 2006-01-19 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ Pdgf受容体阻害剤としてのn−置換三環状3−アミノピラゾール
JP2008528468A (ja) 2005-01-21 2008-07-31 アステックス・セラピューティクス・リミテッド 医薬化合物
JP2009513615A (ja) 2005-10-28 2009-04-02 アストラゼネカ アクチボラグ 癌の治療においてチロシンキナーゼ阻害剤として使用するための4−(3−アミノピラゾール)ピリミジン誘導体
JP2013528580A (ja) 2010-04-30 2013-07-11 アステックス、セラピューティックス、リミテッド ピラゾリルキナゾリンキナーゼ阻害剤
US20130274255A1 (en) 2012-04-12 2013-10-17 Development Center For Biotechnology Heterocyclic pyrazole compounds, method for preparing the same and use thereof
JP2015511638A (ja) 2012-03-30 2015-04-20 エージェンシー フォー サイエンス,テクノロジー アンド リサーチ Mnk1およびmnk2調節剤としての二環式ヘテロアリール誘導体、およびその使用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2425677C2 (ru) 2005-01-21 2011-08-10 Астекс Терапьютикс Лимитед Соединения, предназначенные для использования в фармацевтике
WO2008045627A2 (en) 2006-10-06 2008-04-17 Irm Llc Protein kinase inhibitors and methods for using thereof
CA2686378C (en) * 2007-05-04 2012-07-24 Irm Llc Pyrimidine derivatives and compositions as c-kit and pdgfr kinase inhibitors
CA2780892C (en) * 2009-11-13 2017-02-14 Genosco Kinase inhibitors
UY33801A (es) 2010-12-13 2013-06-28 Array Biopharma Inc COMPUESTOS SUSTITUIDOS DE N-(1H-INDAZOL-4IL)IMIDAZO[1,2-a]PIRIDIN-3-CARBOXAMIDA COMO INHIBIDORES DE LA TIROSINA QUINASA RECEPTORA DE TIPO III
WO2013142382A1 (en) * 2012-03-22 2013-09-26 Genosco Substituted pyridopyrimidine compounds and their use as flt3 inhibitors
US9938273B2 (en) 2015-12-07 2018-04-10 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
CN119792569A (zh) 2018-01-10 2025-04-11 财团法人生物技术开发中心 抗体protac偶联物

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006502097A (ja) 2002-05-15 2006-01-19 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ Pdgf受容体阻害剤としてのn−置換三環状3−アミノピラゾール
JP2008528468A (ja) 2005-01-21 2008-07-31 アステックス・セラピューティクス・リミテッド 医薬化合物
JP2009513615A (ja) 2005-10-28 2009-04-02 アストラゼネカ アクチボラグ 癌の治療においてチロシンキナーゼ阻害剤として使用するための4−(3−アミノピラゾール)ピリミジン誘導体
JP2013528580A (ja) 2010-04-30 2013-07-11 アステックス、セラピューティックス、リミテッド ピラゾリルキナゾリンキナーゼ阻害剤
JP2015511638A (ja) 2012-03-30 2015-04-20 エージェンシー フォー サイエンス,テクノロジー アンド リサーチ Mnk1およびmnk2調節剤としての二環式ヘテロアリール誘導体、およびその使用
US20130274255A1 (en) 2012-04-12 2013-10-17 Development Center For Biotechnology Heterocyclic pyrazole compounds, method for preparing the same and use thereof

Also Published As

Publication number Publication date
CN114502553A (zh) 2022-05-13
AU2020337883B2 (en) 2025-08-28
WO2021041276A1 (en) 2021-03-04
EP4017853A4 (en) 2023-08-30
US12448394B2 (en) 2025-10-21
MX2022002062A (es) 2022-04-25
TWI759829B (zh) 2022-04-01
AU2020337883A1 (en) 2022-03-24
CN114502553B (zh) 2024-07-26
TW202115087A (zh) 2021-04-16
EP4017853A1 (en) 2022-06-29
CA3151821A1 (en) 2021-03-04
US20220289759A1 (en) 2022-09-15
KR20220051365A (ko) 2022-04-26
BR112022003383A2 (pt) 2022-05-17
JP2022545019A (ja) 2022-10-24

Similar Documents

Publication Publication Date Title
JP7189956B2 (ja) Sos1阻害剤としての新規なベンジルアミノ置換ピリドピリミジノンおよび誘導体
JP5871896B2 (ja) B−rafキナーゼインヒビター
CN114375202A (zh) 抗癌组合疗法
JP7206188B2 (ja) Iii型受容体チロシンキナーゼ阻害剤としてのキノキサリン化合物
JP2020504742A (ja) 新規のベンジルアミノ置換キナゾリンおよびsos1阻害剤としての誘導体
JP2020503374A (ja) Bcl6阻害剤としての新規の6−アミノキノリノン化合物および誘導体
JP2021514373A (ja) Egfr阻害剤としての新たなベンズイミダゾール化合物および誘導体
KR20150027121A (ko) 신규 화합물
CA2601983A1 (en) Substituted heterocycles and their use as chk1, pdk1 and pak inhibitors
JP2020519588A (ja) 腫瘍を治療するための薬剤の製造におけるbtk阻害剤との組み合わせでのezh2阻害剤の使用
TWI759829B (zh) 作為第iii型受體酪胺酸激酶抑制劑之雜環吡唑衍生物
RU2833004C2 (ru) Производные гетероциклического пиразола как ингибиторы рецепторной тирозикиназы типа III
WO2023008577A1 (ja) Ras/Raf結合阻害化合物
HK40012508A (en) Quinoxaline compounds as type iii receptor tyrosine kinase inhibitors
HK40012508B (en) Quinoxaline compounds as type iii receptor tyrosine kinase inhibitors

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20220329

RD01 Notification of change of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7426

Effective date: 20220329

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230809

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230809

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240730

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20240731

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20241030

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20241227

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250124

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250218

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250313

R150 Certificate of patent or registration of utility model

Ref document number: 7651557

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150